BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26853320)

  • 1. Rationale and Prospects of Targeting Bacterial Two-component Systems for Antibacterial Treatment of Cystic Fibrosis Patients.
    Velikova N; Wells JM
    Curr Drug Targets; 2017; 18(6):687-695. PubMed ID: 26853320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bacterial sinusitis can be a focus for initial lung colonisation and chronic lung infection in patients with cystic fibrosis.
    Aanæs K
    J Cyst Fibros; 2013 Sep; 12 Suppl 2():S1-20. PubMed ID: 24064077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.
    Conway SP; Brownlee KG; Denton M; Peckham DG
    Am J Respir Med; 2003; 2(4):321-32. PubMed ID: 14719998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way?
    Banerjee D; Stableforth D
    Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current microbiological data on lower respiratory tract infection in cystic fibrosis. Part I: Isolated microorganisms and their clinical significance].
    Coman G; Petraru E; Dahorea C; Anton DT
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):580-7. PubMed ID: 23077957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections.
    Chmiel JF; Aksamit TR; Chotirmall SH; Dasenbrook EC; Elborn JS; LiPuma JJ; Ranganathan SC; Waters VJ; Ratjen FA
    Ann Am Thorac Soc; 2014 Sep; 11(7):1120-9. PubMed ID: 25102221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa.
    Klepac-Ceraj V; Lemon KP; Martin TR; Allgaier M; Kembel SW; Knapp AA; Lory S; Brodie EL; Lynch SV; Bohannan BJ; Green JL; Maurer BA; Kolter R
    Environ Microbiol; 2010 May; 12(5):1293-303. PubMed ID: 20192960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.
    Gilligan PH; Downey DG; Elborn JS; Flume PA; Funk S; Gilpin D; Kidd TJ; McCaughan J; Millar BC; Murphy PG; Rendall JC; Tunney MM; Moore JE
    J Clin Microbiol; 2018 Sep; 56(9):. PubMed ID: 29875191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving epidemiology of Pseudomonas aeruginosa and the Burkholderia cepacia complex in cystic fibrosis lung infection.
    Govan JR; Brown AR; Jones AM
    Future Microbiol; 2007 Apr; 2(2):153-64. PubMed ID: 17661652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New treatments for emerging cystic fibrosis pathogens other than Pseudomonas.
    Waters V
    Curr Pharm Des; 2012; 18(5):696-725. PubMed ID: 22229574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cystic fibrosis: infection.
    Høiby N
    Schweiz Med Wochenschr; 1991 Jan; 121(4):105-9. PubMed ID: 1900640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology and management of pulmonary infections in cystic fibrosis.
    Gibson RL; Burns JL; Ramsey BW
    Am J Respir Crit Care Med; 2003 Oct; 168(8):918-51. PubMed ID: 14555458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenicity of microbes associated with cystic fibrosis.
    Hutchison ML; Govan JR
    Microbes Infect; 1999 Oct; 1(12):1005-14. PubMed ID: 10617932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary infections in patients with cystic fibrosis.
    Rajan S; Saiman L
    Semin Respir Infect; 2002 Mar; 17(1):47-56. PubMed ID: 11891518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel Approaches to Multidrug-Resistant Infections in Cystic Fibrosis.
    Murray TS; Stanley G; Koff JL
    Infect Dis Clin North Am; 2024 Mar; 38(1):149-162. PubMed ID: 38280761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Respiratory bacterial infections in cystic fibrosis.
    Ciofu O; Hansen CR; Høiby N
    Curr Opin Pulm Med; 2013 May; 19(3):251-8. PubMed ID: 23449384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimicrobial resistance, respiratory tract infections and role of biofilms in lung infections in cystic fibrosis patients.
    Ciofu O; Tolker-Nielsen T; Jensen PØ; Wang H; Høiby N
    Adv Drug Deliv Rev; 2015 May; 85():7-23. PubMed ID: 25477303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Bacterial isolates from respiratory samples of pediatric patients with cystic fibrosis and their distribution by ages].
    Busquets NP; Baroni MR; Ochoteco MC; Zurbriggen ML; Virgolini S; Meneghetti FG
    Rev Argent Microbiol; 2013; 45(1):44-9. PubMed ID: 23560788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quorum Sensing as Antivirulence Target in Cystic Fibrosis Pathogens.
    Scoffone VC; Trespidi G; Chiarelli LR; Barbieri G; Buroni S
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Microbiological diagnosis of bronchopulmonary colonization-infection in cystic fibrosis].
    Oliver A; Alarcón T; Caballero E; Cantón R
    Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):89-104. PubMed ID: 19232782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.